Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.30 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114173 | 0.94 | PIK3CD (0.40) | YTHDC1PIK3CAMTORPIK3CDATR | |
| SCHEMBL31372903 | 0.94 | PIK3CD (0.40) | YTHDC1PIK3CAMTORPIK3CDATR | |
| SCHEMBL10262783 | 0.88 | YTHDC1 (0.37) | YTHDC1PIK3CAMTORPIK3CDATR | |
| SCHEMBL9936929 | 0.85 | YTHDC1 (0.42) | YTHDC1ATR | |
| SCHEMBL9937128 | 0.84 | PIK3CD (0.36) | YTHDC1PIK3CAMTORPIK3CDATR | |
| SCHEMBL20903687 | 0.83 | YTHDC1 (0.42) | YTHDC1PDE10A | |
| SCHEMBL18050669 | 0.83 | YTHDC1 (0.36) | YTHDC1 | |
| SCHEMBL19242068 | 0.82 | YTHDC1 (0.35) | YTHDC1PIK3CAMTORPIK3CDATR | |
| SCHEMBL28673967 | 0.78 | YTHDC1 (0.37) | YTHDC1 | |
| SCHEMBL21523565 | 0.77 | YTHDC1 (0.34) | YTHDC1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3268373-B1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| EP-3268373-B1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-107406462-B | Tricyclic DLK inhibitors and uses thereof | 豪夫迈·罗氏有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-10131675-B2 | Tricyclic DLK inhibitors and uses thereof | GENENTECH, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| EP-3268373-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2018-01-17 | — | — | EP | disclosed |
| US-20170369510-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170369510-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| WO-2016142310-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016142310-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10131675-B2 | Tricyclic DLK inhibitors and uses thereof | NLK, DCLK2, DLK1 | YTHDC1 4652/4885PIK3CA 1685/4885MTOR 285/4885 |
| US-20170369510-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | NLK, DCLK2, DLK1 | YTHDC1 4652/4885PIK3CA 1685/4885MTOR 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.